Among the 230,000 patients diagnosed with prostate cancer each year in the United States, 81% have localized cancer, 12% have node-positive disease, and 4% have distant metastatic disease (with the remainder unstaged). While there are numerous randomized trials to guide the management of patients with localized and metastatic cancers, few trials have specifically addressed node-positive patients—or even included any of these patients at all. As a result, there is uncertainty regarding the optimal treatment in this setting. Node-positive prostate cancer is categorized as “stage IV,” but patient management likely needs to be different from that for distant metastatic disease, and a proportion of node-positive patients are likely curable with aggressive multimodality therapy.
This article summarizes the existing literature on use of radiotherapy for node-positive prostate cancer, as well as the associated outcomes. Studies that examined the use of radiotherapy as definitive treatment (discussed below and outlined in Table 1) and as adjuvant therapy after radical prostatectomy (discussed below and outlined in Table 2) are reviewed separately.
Use of Radiotherapy as Definitive Treatment
Efficacy of androgen deprivation therapy (ADT) alone as treatment for node-positive prostate cancer
ADT alone is one treatment option for patients with node-positive prostate cancer. In the European Organisation for Research and Treatment of Cancer (EORTC) 30846 trial, 234 men with node-positive (pN1-3) prostate cancer were randomized from 1986 to 1998 to receive either immediate ADT or delayed ADT (given at time of clinical progression).[3,4] Patients were confirmed to be node-positive after lymphadenectomy, but no prostatectomy or other local treatment was performed. ADT consisted of either orchiectomy or treatment with gonadotropin-releasing hormone (GnRH) analog plus anti-androgen.
After a median follow-up of 13 years, the median overall survival (OS; 6.1 years with delayed ADT vs 7.6 years with immediate ADT) and 10-year prostate cancer–specific survival (44.4% for delayed ADT vs 47.9% for immediate ADT) were not statistically significantly different between the two arms. (P values were not reported.) Given these results, it is not clear if immediate ADT is better than a watch-and-wait approach for these patients.
Addition of definitive radiotherapy to immediate ADT
Definitive radiotherapy significantly improves OS over ADT alone for patients with locally advanced prostate cancer, as demonstrated by two randomized trials that compared ADT with ADT plus radiotherapy. The absolute survival benefit from radiotherapy in these trials was 8% to 10%.[5,6] Whether such benefit extends to patients with even more aggressive disease—node-positive prostate cancer—has not been definitively demonstrated. However, several retrospective studies provide support for a benefit from radiotherapy in these patients.[7-9]
In an analysis of patients treated at The University of Texas MD Anderson Cancer Center, Zagars et al compared the outcomes of 255 patients with staging lymphadenectomy–proven pathologically node-positive (pN+) disease who were treated with indefinite ADT alone (n = 183) vs ADT plus radiotherapy to a median dose of 68 Gy (n = 72). None of the patients had a prostatectomy. ADT consisted of either orchiectomy (58%) or medical castration (42%, using either a GnRH agonist or megestrol and diethylstilbestrol).
Patients who received ADT plus radiotherapy had better 10-year OS (46% for ADT alone vs 67% for ADT plus radiotherapy; P = .008), local control (49% vs 89%; P < .001), freedom from metastasis (56% vs 85%; P = .006), and freedom from recurrence (25% vs 80%; P < .001); however, patients treated with ADT alone had more aggressive cancers. On multivariate analysis, which adjusted for Gleason score, T stage, and pretreatment prostate-specific antigen (PSA) level, the addition of radiotherapy increased freedom from relapse or rising PSA (hazard ratio [HR] = 6.0; 95% confidence interval [CI], 3.1–11.5), freedom from distant metastasis (HR = 2.7; 95% CI, 1.3–5.6), and OS (HR = 2.1; 95% CI, 1.2–3.9).
Two studies analyzing data from SEER (Surveillance, Epidemiology and End Results) also suggest a survival benefit from radiotherapy. In a study from Tward et al, a total of 1,100 patients with node-positive disease diagnosed from 1988 to 2006 were included. The authors grouped both external beam radiation therapy (EBRT) and brachytherapy patients together, and compared them with a group that received no radiotherapy. After a median follow-up of 7.5 years, men who received radiotherapy had greater 5-year OS (56.2% for no radiotherapy vs 67.8% for radiotherapy; multivariate HR = 0.68; P < .01) and prostate cancer–specific survival (71.1% for no radiotherapy vs 78.1% for radiotherapy; multivariate HR = 0.67; P < .01). Another SEER analysis from Rusthoven et al showed improved 10-year OS and prostate cancer–specific survival in patients treated with radiotherapy vs no local therapy. It is important to note that SEER data do not definitively distinguish patients with clinical (radiographic) or pathologic (from biopsy or nodal dissection) node-positive disease, and no information on ADT is available.
Taken together, these retrospective studies have consistently demonstrated a survival benefit from radiotherapy compared with conservative management for node-positive prostate cancer, and suggest that definitive therapy with radiation is reasonable to consider. However, these studies are limited by their retrospective nature and patient selection factors that can potentially confound the comparisons. It is important to note, however, that patients with node-positive cancer, while stage IV, can achieve long-term survival; these retrospective studies strongly suggest that a proportion of patients are curable with aggressive therapy. Future prospective, randomized studies are needed to more definitively demonstrate the potential benefit of radiotherapy in node-positive disease. Current guidelines recommend either radiotherapy plus long-term ADT (2 to 3 years) or long-term ADT alone as treatment options.
Radiotherapy with or without ADT
For patients with high-risk and locally advanced prostate cancer, multiple randomized trials have demonstrated improved OS from adding ADT to definitive radiotherapy,[10-13] establishing this combination as a standard of care. Two of these trials included patients with node-positive disease, and subgroup analyses of these patients provide support for adding ADT to radiotherapy in this setting.
The Radiation Therapy Oncology Group (RTOG) 85-31 trial randomized 977 men with either T3 or node-positive disease to EBRT alone vs EBRT plus ADT. The ADT regimen was goserelin indefinitely or until progression, and radiotherapy was 65–70 Gy as definitive treatment or 60–65 Gy in the post-prostatectomy setting. In a subgroup analysis of the 173 patients with pathologic node-positive disease, the combined-therapy group had significantly better 5-year biochemical control (54% combined vs 10% for radiotherapy alone; P < .0001) and distant metastasis–free survival (P = .026; no percentages reported). OS was 72% for combined therapy vs 62% for radiotherapy alone (P = .23), but this subgroup analysis was not adequately powered to detect a survival difference. On multivariate analysis, radiotherapy alone compared with combined therapy was associated with increased overall mortality (HR = 1.62; P = .03), disease-specific failure (HR = 2.12; P = .014), metastatic failure (HR = 2.54; P = .0005), and biochemical failure (HR = 3.82; P < .0001).
Granfors et al randomized 91 patients to either EBRT alone or radiotherapy plus ADT. All patients underwent surgical lymph node staging (but not prostatectomy) prior to randomization, and 43% (n = 39) of patients were pathologic node-positive. The radiation dose delivered was 65 Gy, and androgen deprivation was achieved by bilateral orchiectomy. In a subgroup analysis of pathologically node-positive patients, after a median follow-up of 9.7 years, patients who received combined therapy had better OS compared with patients who received radiotherapy alone (log rank P = .005; percentages not reported).
With numerous randomized trials demonstrating a survival benefit from adding ADT to radiotherapy for patients with intermediate-risk,[16,17] high-risk, and locally advanced prostate cancers,[11-13,18-20] the results from these subgroup analyses of trials suggest that the benefit of adding ADT to definitive radiotherapy likely applies to patients with node-positive prostate cancer.
1. Fast Stats: An interactive tool for access to SEER cancer statistics. Available at www.seer.cancer.gov/faststats. Accessed December 8, 2014.
2. Mohler JL, Kantoff PW, Armstrong AJ, et al. Prostate cancer, version 2.2014. J Natl Compr Canc Netw. 2014;12:686-718.
3. Schröder FH, Kurth KH, Fossa SD, et al. Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of European Organisation for the Research and Treatment of Cancer 30846—a phase III study. J Urol. 2004;172:923-7.
4. Schröder FH, Kurth KH, Fossa SD, et al. Early versus delayed endocrine treatment of T2-T3 pN1-3 M0 prostate cancer without local treatment of the primary tumour: final results of European Organisation for the Research and Treatment of Cancer protocol 30846 after 13 years of follow-up (a randomised controlled trial). Eur Urol. 2009;55:14-22.
5. Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 2009;373:301-8.
6. Warde P, Mason M, Ding K, et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet. 2011;378:2104-11.
7. Zagars GK, Pollack A, von Eschenbach AC. Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer. Urology. 2001;58:233-9.
8. Tward JD, Kokeny KE, Shrieve DC. Radiation therapy for clinically node-positive prostate adenocarcinoma is correlated with improved overall and prostate cancer-specific survival. Pract Radiat Oncol. 2013;3:234-40.
9. Rusthoven CG, Carlson JA, Waxweiler TV, et al. The impact of definitive local therapy for lymph node-positive prostate cancer: a population-based study. Int J Radiat Oncol Biol Phys. 2014;88:1064-73.
10. Denham JW, Steigler A, Lamb DS, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol. 2005;6:841-50.
11. Roach M, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. 2008;26:585-91.
12. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360:103-6.
13. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005;61:1285-90.
14. Lawton CA, Winter K, Grignon D, Pilepich MV. Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31. J Clin Oncol. 2005;23:800-7.
15. Granfors T, Modig H, Damber JE, Tomic R. Long-term follow-up of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone. J Urol. 2006;176:544-7.
16. Jones CU, Hunt D, McGowan DG, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med. 2011;365:107-18.
17. D’Amico AV, Chen MH, Renshaw AA, et al. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008;299:289-95.
18. Denham JW, Steigler A, Lamb DS, et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol. 2011;12:451-9.
19. Bolla M, de Reijke TM, Van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009;360:2516-27.
20. Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008;26:2497-504.
21. Messing EM, Manola J, Sarosdy M, et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999;341:1781-8.
22. Messing EM, Manola J, Yao J, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006;7:472-9.
23. Wiegel T, Bottke D, Steiner U, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol. 2009;27:2924-30.
24. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA. 2006;296:2329-35.
25. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009;181:956-62.
26. Da Pozzo LF, Cozzarini C, Briganti A, et al. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy. Eur Urol. 2009;55:1003-11.
27. Briganti A, Karnes RJ, Da Pozzo LF, et al. Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis. Eur Urol. 2011;59:832-40.
28. Abdollah F, Karnes RJ, Suardi N, et al. Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer. J Clin Oncol. 2014 Sep 22. [Epub ahead of print]
29. Kaplan JR, Kowalczyk KJ, Borza T, et al. Patterns of care and outcomes of radiotherapy for lymph node positivity after radical prostatectomy. BJU Int. 2013;111:1208-14.
30. Ost P, Cozzarini C, De Meerleer G, et al. High-dose adjuvant radiotherapy after radical prostatectomy with or without androgen deprivation therapy. Int J Radiat Oncol Biol Phys. 2012;83:960-5.
31. Bastide C, Rossi D, Lechevallier E, et al. Seminal vesicle invasion: what is the best adjuvant treatment after radical prostatectomy? BJU Int. 2012;109:525-30; discussion 31-2.
32. Yuh BE, Ruel NH, Mejia R, et al. Standardized comparison of robot-assisted limited and extended pelvic lymphadenectomy for prostate cancer. BJU Int. 2013;112:81-8.
33. Bivalacqua TJ, Pierorazio PM, Gorin MA, et al. Anatomic extent of pelvic lymph node dissection: impact on long-term cancer-specific outcomes in men with positive lymph nodes at time of radical prostatectomy. Urology. 2013;82:653-8.
34. Allaf ME, Palapattu GS, Trock BJ, et al. Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol. 2004;172:1840-4.
35. Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol. 2014;65:124-37.
36. Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007;177:2106-31.
37. Fizazi K, Laplanche A, Lesaunier F, et al. Docetaxel-estramustine in localized high-risk prostate cancer: results of the French Genitourinary Tumor Group GETUG 12 phase III trial. J Clin Oncol. 2014;32:5005.
38. Boorjian SA, Thompson RH, Siddiqui S, et al. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J Urol. 2007;178:864-70.
39. Briganti A, Karnes JR, Da Pozzo LF, et al. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol. 2009;55:261-70.
40. Touijer KA, Mazzola CR, Sjoberg DD, et al. Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy. Eur Urol. 2014;65:20-5.
41. Abdollah F, Karnes RJ, Suardi N, et al. Predicting survival of patients with node-positive prostate cancer following multimodal treatment. Eur Urol. 2014;65:554-62.